The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01250171
First received: November 29, 2010
Last updated: December 4, 2012
Last verified: December 2012
  Purpose

This study assessed the effects of a single intravenous dose of secukinumab (AIN457) 10 mg/kg or canakinumab (ACZ885) 10 mg/kg on the signs and symptoms of dry eye. In addition, the pharmacokinetic, pharmacodynamic, and safety profiles of secukinumab and canakinumab were assessed. Blood samples were collected for the analysis of the effect of secukinumab and canakinumab on select biomarkers.


Condition Intervention Phase
Dry Eye
Biological: Secukinumab 10 mg/kg
Biological: Canakinumab 10 mg/kg
Biological: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Intravenous Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Syndrome

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change From Baseline on the National Eye Institute Corneal Staining Scale (NEI-CSS) at Week 4 [ Time Frame: Baseline to Week 4 ] [ Designated as safety issue: No ]
    Corneal staining was done with 2% sodium fluorescein instilled into the lower palpebral conjunctiva of each eye. Staining was assessed in 5 zones of the cornea (central plus 4 quadrants) and rated on a scale of 0 (no staining) to 3 (severe, confluent staining). A mean of the 5 zones for the study eye was calculated. A higher score indicates a drier eye. A negative change score indicates improvement in dryness.


Secondary Outcome Measures:
  • Change From Baseline on the Ora Corneal Staining Scale at Weeks 1, 4, and 8 [ Time Frame: Baseline to Weeks 1, 4, and 8 ] [ Designated as safety issue: No ]
    Corneal staining was done with 2% sodium fluorescein instilled into the lower palpebral conjunctiva of the study eye. Staining was assessed in 3 regions (inferior, superior, and central) of the cornea and rated on a scale of 0 (no staining) to 4 (confluent staining). A mean of the 3 zones was calculated. A higher score indicates a drier eye. A negative change score indicates improvement in dryness.

  • Change From Baseline on the Schirmer Test at Weeks 1, 4, and 8 [ Time Frame: Baseline to Weeks 1, 4, and 8 ] [ Designated as safety issue: No ]
    The Schirmer test measures the production of tears. A small strip of filter paper is placed inside the lower eyelid (conjunctival sac) of each eye and the eyes are kept closed for 5 minutes. The paper is removed and the length of paper that is wet is measured as an index of tear production. The amount of tear production in the study eye was ranked on a 4 point scale: 0=Normal (≥ 15 mm wetting of the paper), 1=Mild (14-9 mm wetting of the paper), 2=Moderate (8-4 mm wetting of the paper), and 3=Severe (< 4 mm wetting of the paper). A higher score indicates a drier eye. A negative change score indicates improvement in dryness.

  • Change From Baseline in Tear Film Breakup Time at Weeks 1, 4, and 8 [ Time Frame: Baseline to Weeks 1, 4, and 8 ] [ Designated as safety issue: No ]
    Tear film breakup time was defined as the time of last blink to the appearance of the first growing micelle after instilling 5 μl of non-preserved 2% sodium fluorescein into the lower palpebral conjunctiva of the study eye. Measurement was repeated 3 times and a mean tear film breakup time calculated. A lower score indicates a drier eye. A positive change score indicates improvement in dryness.

  • Change From Baseline on the Conjunctival Redness Scale (Ora) at Weeks 1, 4, and 8 [ Time Frame: Baseline to Weeks 1, 4, and 8 ] [ Designated as safety issue: No ]
    Conjunctival redness was measured in the study eye at each visit by a masked evaluator. The evaluator compared the patient's study eye with a set of 5 reference photos showing a normal eye and eyes with various degrees of redness. Redness was scored on a scale of 0-5 with a white normal eye = 0 and an eye with the most redness = 5. A higher score indicates more redness. A negative change score indicates improvement in redness.

  • Change From Baseline in the Ocular Surface Disease Index (OSDI) at Weeks 1, 4, and 8 [ Time Frame: Baseline to Weeks 1, 4, and 8 ] [ Designated as safety issue: No ]
    The OSDI is an instrument for measuring dry eye disease severity and effect on vision-related functions. Patients were asked a series of 12 questions; patients responded to the questions in regard to both eyes. Responses ranged from 0=None of the time to 4=All of the time. OSDI was calculated as the sum of the 12 question scores x 25/number of questions answered. The total score ranged from 0-100. A higher score indicates drier eyes. A negative change score indicates improvement in dryness.

  • Desire for Artificial Tear Use at Day 1 and Weeks 1, 4, and 8 [ Time Frame: Day 1 and Weeks 1, 4, and 8 ] [ Designated as safety issue: No ]
    Patients were instructed to record each occurrence of a desire for topical lubricant use in a patient diary. The percentage of patients in each of 6 categories (0-5, 6-10, 11-15, 16-20, 21-25, > 25 times) indicating the number of times a patient records a desire for artificial tear use per day was calculated at each time point. The percentage was calculated using the number of patients with any reported data on that day in the respective treatment group as the denominator.

  • Change From Baseline in Best Corrected Visual Acuity at Weeks 1, 4, and 8 [ Time Frame: Baseline to Weeks 1, 4, and 8 ] [ Designated as safety issue: No ]
    Best corrected visual acuity (BCVA) was assessed in the study eye. BCVA measurements were taken in a standing position using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at an initial testing distance specific to the test charts. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement.


Enrollment: 72
Study Start Date: November 2010
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Secukinumab 10 mg/kg
Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period.
Biological: Secukinumab 10 mg/kg
Secukinumab was prepared in a sterile water solution.
Other Name: AIN457
Experimental: Canakinumab 10 mg/kg
Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period.
Biological: Canakinumab 10 mg/kg
Canakinumab was prepared in a sterile water solution.
Other Name: ACZ885
Placebo Comparator: Placebo
Patients received a single placebo infusion intravenously over a 2 hour period.
Biological: Placebo
The placebo solution for infusion contained 5% glucose.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients age 18-85 with a diagnosis of moderate to severe dry eye.
  • Schirmer test without anesthesia ≥ 1 and < 10 mm wetting over 5 minutes in at least 1 eye.
  • Tear break up time < 7 seconds in at least 1 eye.
  • Corneal staining score ≥ 3 (National Eye Institute [NEI] grading scale).
  • Conjunctival redness of ≥ 1.
  • Ocular surface disease index of modest to severe.
  • Ability to provide informed consent.

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Hemoglobin < 10 g/dl.
  • Total white blood count (WBC) outside the range of 3000-14,000/µl.
  • Platelets < 100,000/µl.
  • Use of ocular, periocular, or systemic steroids within 60 days prior to screening.
  • Use of contact lenses or prior corneal refractive surgery in either eye.
  • Requirement of eye drop use during the study.
  • Anesthetic or neurotrophic corneas.
  • Temporary punctal plugs.
  • Recent or planned exposure to live vaccinations.
  • Other protocol-defined inclusion/exclusion criteria may apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01250171

Locations
United States, Massachusetts
Ora Inc, 300 Brickstone Square,
Andover, Massachusetts, United States, 01810
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01250171     History of Changes
Other Study ID Numbers: CPJMR0092202
Study First Received: November 29, 2010
Results First Received: September 11, 2012
Last Updated: December 4, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
Dry eye
IL17/ IL-1β
Biologic

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 16, 2014